Skip to main
LIVN

Livanova (LIVN) Stock Forecast & Price Target

Livanova (LIVN) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

LivaNova's revenue has shown significant growth, with sales rising by 29% to $803 million in 2024, and management projecting further sales increase to between $940 million and $955 million. The company benefits from its diverse portfolio, primarily in cardiopulmonary solutions and neuromodulation devices, capturing roughly half of its revenue from the US market and a substantial portion from Europe. Additionally, expectations of increasing market share for its aura6000 device, with potential sales reaching up to $280 million by 2029 in a favorable scenario, bolster the optimism for LivaNova's future performance.

Bears say

LivaNova is facing a negative outlook primarily due to anticipated revenue growth slowing to low-single digits, driven by persistent challenges in its Neuromodulation and Cardiovascular segments. The company is also grappling with operating margin contraction and below-consensus earnings expectations, further emphasizing its financial difficulties. Additionally, risks, including potential failure to gain FDA approval for the aura6000 device and slower-than-expected growth in its core businesses, contribute to the unfavorable financial projections.

Livanova (LIVN) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Livanova (LIVN) Forecast

Analysts have given Livanova (LIVN) a Buy based on their latest research and market trends.

According to 8 analysts, Livanova (LIVN) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $67.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $67.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Livanova (LIVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.